Scientific deep-dive
What Is Mazdutide? The Obesity Drug Approved in China, Not the US
Mazdutide is a glucagon/GLP-1 dual agonist approved in China for chronic weight management but unavailable in the US. We cover what the approval actually authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad does not make a US-sold vial legitimate.
Mazdutide is a once-weekly glucagon/GLP-1 dual agonist developed by Innovent Biologics under license from Eli Lilly. It is unusual among the drugs people research: it is not a pipeline compound waiting on trial results, and it is not a gray-market peptide. It is an approved medicine — approved by China's NMPA for chronic weight management, and reported in the literature as a first approval for its class [1]. It has no US approval, which is the whole reason it is confusing. The closest comparison is survodutide, which targets the identical receptor pair but is approved nowhere.
Approved, but not where you are
Mazdutide received Chinese regulatory approval for chronic weight management in adults with obesity or overweight who also have at least one weight-related comorbidity, and a further approval covering glycemic control in type 2 diabetes [1]. That is a genuine marketing authorization from a major regulator — not an emergency pathway and not a research exemption.
What it does, mechanically
Mazdutide is described as a mammalian oxyntomodulin analog. Alongside the GLP-1 effects familiar from semaglutide — insulin secretion, lower blood glucose, reduced appetite — the glucagon-receptor arm may increase energy expenditure and improve hepatic fat metabolism [1]. That is the same second lever retatrutide pulls, except retatrutide adds a third receptor (GIP) and mazdutide does not.
| Drug | Receptors | Status |
|---|---|---|
| Semaglutide | GLP-1 | FDA approved |
| Tirzepatide | GIP + GLP-1 | FDA approved |
| Mazdutide | Glucagon + GLP-1 | Approved in China; no US approval |
| Survodutide | Glucagon + GLP-1 | Investigational |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational |
The trial evidence
The pivotal work was conducted in Chinese adults. A once-weekly mazdutide trial in adults with obesity or overweight was published in the New England Journal of Medicine in 2025 [2], and head-to-head work against dulaglutide in Chinese adults with type 2 diabetes appeared in Nature in 2026 [3].
One limitation is worth stating plainly rather than burying: the efficacy and safety dataset is predominantly Chinese. That is not a criticism of the trials, which were designed for the market that approved the drug. It does mean the usual caution about generalizing across populations applies more than it would for a drug with a multi-region phase 3 program.
“Mazdutide peptide” is not the approved product
A meaningful share of English-language searches for mazdutide pair it with the word “peptide” — the same pattern that surrounds every unapproved-in-the-US obesity compound. Material sold that way is not the Chinese approved product routed to you; it is unapproved material of unverified identity and purity. The approval belongs to a specific manufactured product under a specific regulator, and it does not transfer to a vial from a research-chemical vendor.
Frequently Asked Questions
References
- 1.Shirley M. Mazdutide: First Approval. Drugs. 2025. PMID: 41028652.
- 2.Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. PMID: 40421736.
- 3.Nature (2026). Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026. PMID: 41407860.
Related research
GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)
A living tracker of the next-generation GLP-1 and incretin drugs in development — retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide, and the first approved oral pill orforglipron (Foundayo) — with development stage, peak reported weight loss, and a link to each fully-cited deep-dive.
7 min read
Mazdutide (IBI362): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence
Mazdutide is a GLP-1/glucagon dual agonist approved in China in 2025 for weight management (not FDA-approved). What the phase 3 GLORY-1 trial showed: -14% body weight at 48 weeks on 6 mg, how it compares to semaglutide and tirzepatide, and what its approval means for US patients.
9 min read
What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 3
Survodutide is an investigational glucagon/GLP-1 dual agonist with phase 3 obesity data published in 2026. We cover the mechanism, the trial evidence in obesity and MASH, why no head-to-head against tirzepatide exists, and why there is no dose to follow.
5 min read
Mounjaro Body Odor: The Evidence and the One Red Flag
Does Mounjaro cause body odor? Tirzepatide doesn't act on sweat glands — keto breath, dehydration, and dry mouth do. The honest mechanisms and the DKA red flag.
9 min read
What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)
GIP stands for glucose-dependent insulinotropic polypeptide — a 42-amino-acid gut hormone secreted by K-cells in the upper small intestine that, alongside GLP-1, accounts for the post-meal "incretin effect" (the disproportionately greater insulin response to oral glucose vs IV glucose). Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for obesity/OSA) is the first FDA-approved dual GIP / GLP-1 receptor agonist — the §12.1 mechanism-of-action language in both DailyMed labels states verbatim that "tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist." SURPASS-2 (Frías et al., NEJM 2021, PMID 34170647) demonstrated that dual GIP+GLP-1 agonism produces greater HbA1c reduction and greater weight loss than the single GLP-1 agonist semaglutide 1 mg head-to-head. The next-generation triple agonist retatrutide adds glucagon-receptor agonism on top of GIP+GLP-1 (Jastreboff Phase 2, NEJM 2023, PMID 37366315) — investigational, NOT FDA-approved as of 2026-05-09. This article explains what GIP is, where the receptor lives, why dual agonism beats single GLP-1 mechanism, and what the verbatim FDA labels actually say about tirzepatide's mechanism.
13 min read
Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs That Could Reach Approval in 2026-2027
Survodutide (Boehringer Ingelheim/Zealand), maridebart cafraglutide (MariTide, Amgen), and ecnoglutide (Sciwind/Pfizer) are the three most-watched GLP-1 pipeline drugs that aren't being made by Lilly or Novo. We walk through the verified phase 2 and phase 3 data on each, the mechanisms, and where they fit in the post-CagriSema, post-retatrutide landscape.
11 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Sesame Care
Brand-name GLP-1s at cash prices, no compounding
Pricing Compare
Get started →Try Ageless
Lowest-tier compounded GLP-1 in injection, troche and sublingual forms
Pricing Compare
Get started →Sunlight
Compounded GLP-1 with unlimited telehealth visits and free shipping
Pricing Compare
Get started →